First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

First Tracks Biotherapeutics (TRAX) will announce top-line celiac disease trial data and host an investor webcast on October 12, 2026.

Rhea-AI Impact

(Very High)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

First Tracks Biotherapeutics (TRAX) will announce top-line celiac disease trial data and host an investor webcast on October 12, 2026. The data cover Cohort 1 of the global Phase 1b trial of investigational ANB033, a gluten-challenge study assessing prevention of mucosal damage. Results will appear in a morning press release and be reviewed at 8:30 a.m. ET/5:30 a.m. PT. A webcast replay will remain available for at least 30 days.

Key Figures

Top-line data date: Oct. 12, 2026

Top-line data date: Oct. 12, 2026; Cohort 1 of the Phase 1b ANB033 celiac-disease trial

Key Terms

cd122 antagonist

1 terms

cd122 antagonist medical

"investigational ANB033, a CD122 antagonist, in celiac disease"

A CD122 antagonist is a drug that blocks the CD122 protein, a key part of the receptor that immune signals use to activate certain white blood cells. By preventing those signals, the drug can dial down immune activity—useful for treating autoimmune diseases, preventing transplant rejection, or altering anti‑cancer immune responses. Investors care because such a compound’s effectiveness and side‑effect profile drive clinical trial success and commercial potential, like adjusting a thermostat to change a room’s temperature.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/11/2026 - 04:00 PM

SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT.

A live webcast of the call will be available on the First Tracks website at: https://ir.firsttracksbio.com/news-events/events. The data will be provided in a morning press release and presented during the webcast. A replay of the webcast will be available for at least 30 days following the event.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn.

Investor Contact:
Nick Montemarano
Vice President, Investor Relations
858.732.0178
investors@firsttracksbio.com